Vapotherm Inc. Announces Commercial Launch of Flowrest® Homecare Device
Published: Jul 26, 2011
STEVENSVILLE, Md., July 26, 2011 /PRNewswire-USNewswire/ -- Vapotherm announced today the launch of Flowrest®, a High Flow Therapy device developed specifically for homecare and other low acuity environments. The initial launch will focus on the U.S. and European markets.
Vapotherm's Flowrest® is designed specifically for chronic respiratory patients in home and other extended care environments. According to the World Health Organization, chronic respiratory diseases impact hundreds of millions of people worldwide, with asthma and COPD alone totaling almost 300 million globally. Other chronic conditions include allergic rhinitis, pulmonary fibrosis and pulmonary hypertension. In the U.S. alone, COPD affects more than 16 million and over 1 million patients are prescribed long-term oxygen therapy. Flowrest® is indicated to deliver heated, humidified breathing gases via nasal cannula at flow rates from 15 to 35 liters per minute.
"In response to pre-launch demand, we are excited to begin shipping Flowrest® to our customers in the U.S. and Europe," said Nick Macmillan, Home Care Segment Manager at Vapotherm. "The Flowrest® provides patients with a new option for respiratory assistance that overcomes the well documented issues associated with mask therapies including problems with patient compliance and comfort. Through our patented technology, we have empowered the simple and comfortable nasal cannula to provide higher levels of respiratory support."
Robert Storey, CEO of Vapotherm, commenting on the launch stated, "We wanted to provide a solution to the constant requests we received from hospital customers for a homecare option. Worldwide, health care systems are looking for ways to get patients out of the hospital faster and sustain them at home to minimize the risk that they will have to return to the hospital. Flowrest® is our answer to the continuity of care in High Flow Therapy."
Vapotherm has been the leading provider of High Flow Therapy devices to hospitals for over ten years, and created the category of High Flow Nasal Cannula beginning in 2001 with its first device, the 2000i. The Company's flagship product, the Precision Flow®, is currently used in hospitals worldwide in adult, pediatric and neonatal applications. The Flowrest® was created to fill the need for High Flow Therapy outside of the short term acute care environment.
Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and homecare use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive respiratory therapy technologies, especially for the treatment of acute and chronic breathing disorders. For more information, visit www.vtherm.com.
198 Log Canoe Circle
Stevensville, MD 21666
Phone (410) 604-3977
Fax (410) 604-3978
Contact: Kevin Thibodeau, Executive Vice President of Sales and Marketing
SOURCE Vapotherm, Inc.